Vascular CT (Fenestra® VC) of neck tumor in transgenic mice harboring a conditional knock-in of the Pax3:Fkhr oncogene causing alveolar rhabdomyosarcomas. Neck tumor aggressively displaces adjacent vessels increasing volume of blood feeding tumor, an effect not seen from right sternocleidomastoid.

Read more ›

Posted in Uncategorized


New CRO Services

CRO Services

MediLumine launches CRO services for method development, formulation characterization and non-GMP batch manufacture of potential therapeutic & imaging compounds used in the life sciences.

Our proprietary drug delivery, theranostic and imaging platforms employing lipid, polymer, polysaccharide, hydrogel, and nanoparticle technologies have made us a partner of choice for outsource of R&D in the life sciences.

Read more ›

Posted in Uncategorized


Characterizing Time Course of Contrast Enhancement, Biodistribution, Elimination Pathway and Hepatocyte Selectivity of Fenestra Nanoemulsions

Characterizing Time Course of Contrast Enhancement, Biodistribution, Elimination Pathway and Hepatocyte Selectivity of Fenestra Nanoemulsions

Work on characterizing Fenestra emulsions started in early 90s’ and was first presented at 1994 Controlled Release Society Annual Meeting in Nice France. This preliminary work confirmed the almost exclusive hepatobiliary route for the elimination of these lipid emulsions in bile.

Read more ›

Posted in blog, Literature Review, News
Tags: ,

The Various Administration Routes of Fenestra VC

Time Course of Contrast Enhancement for the Various Injection Routes of Fenestra VC

Here is link to poster that looks at time course of contrast enhancement for the various injection routes of Fenestra VC: http://www.medilumine.com/wp-content/uploads/2015/07/AMI-2006-Poster-244.pdf

Read more ›

Posted in Uncategorized


New Product for High Resolution microCT

MediLumine’s NEW Mvivo gold nanoparticles enable long lasting vascular contrast for high resolution microCT.

• Low-dose
• Long lasting high resolution vascular contrast
• Ideal for tumor imaging studies

microCT of three mice 26 hours post-injection with Mvivo Au at doses of 100 uL (middle),

Read more ›

Posted in Uncategorized


Fenestra Launch

wmic-2
Fenestra Launch

MediLumine’s Fenestra® imaging agents for preclinical computed tomography will be presented at the upcoming WMIC.

Fenestra® LC and Fenestra® VC imaging agents are used for a wide array of applications in preclinical computed tomography and molecular imaging. These hepatocyte selective nanoemulsions help to enable co-registration of soft tissue CT data for multimodal molecular imaging,

Read more ›

Posted in News
Tags: , ,

Time Course of Contrast Enhancement Using Fenestra VC

Time Course of Contrast Enhancement Using Fenestra VC

A benchmark study for the time course of contrast enhancement of Fenestra® VC was performed on a flat-panel eXplore Locus and an injection dose of 10 mL/kg. Peak enhancement in C57 mice hearts occurred 0.25 hours with a 340 HU enhancement over baseline.

Read more ›

Posted in blog, Literature Review
Tags: ,